Tetrahydrocannabihexol
Viewing r1 — May 13, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
THCH (tetrahydrocannabihexol) — also known as parahexyl — is a cannabinoid of the dibenzopyran class. It is a direct homolog of Δ9-THC, its six-carbon side chain producing stronger cannabinoid receptor binding than conventional THC.[1][2] It activates these receptors more completely than THC, generating a more intense cannabis-type experience.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Δ9-THC, Δ8-THC, THCP +3 moreΔ9-THC, Δ8-THC, THCP, THCB, HHC, Synthetic cannabinoids show less
Roger Adams first synthesized it under the name parahexyl in 1941–1942, as part of systematic work to identify cannabis's active principles. It was considered a purely synthetic compound for nearly eighty years, until researchers identified it as a trace natural component of cannabis in 2020.[3] Semi-synthetic products reached online markets by 2021–2022,[4] and Japan imposed emergency controls after documented hospitalisations.[5]
Subjective effects include sedation, euphoria, appetite enhancement, time alteration, and sensory intensification. The experience resembles cannabis but is steeper — the margin between comfortable and overwhelming narrows because THCH activates receptors more completely than THC can. Anxiety, paranoia, confusion, and hallucinations are characteristic unsought effects; at least one documented case involved loss of consciousness lasting two days.
Dependence liability is presumed at least equivalent to cannabis; no lethal dose data exist for any species. As a full receptor activator — unlike THC, which is partial — THCH can push effects beyond what plant cannabis reaches, including prolonged unconsciousness documented in real cases. Understanding is extremely thin: it rests on a single isolation study, mouse metabolism data, and a handful of adverse event reports.
History[edit]
Discovery
Roger Adams and collaborators synthesized the compound they called parahexyl (also synhexyl) around 1941–1942, as part of systematic work to identify the active principles of cannabis.[6] Early pharmacological testing in mice confirmed cannabis-like effects — catalepsy and motor impairment.[7] The compound remained classified as a purely synthetic structural analog for nearly eighty years.
Natural isolation and market emergence
In 2020, researchers identified Δ9-THCH as a trace natural component of the FM2 medicinal cannabis variety, establishing it as a true phytocannabinoid for the first time.[3] Semi-synthetic products appeared on online markets in Japan, Europe, and the United States within two years.[8][4]
Regulatory response
Japan designated both Δ8- and Δ9-THCH as controlled substances in August 2023, following at least nine documented adverse events.[5] The UK's Advisory Council on the Misuse of Drugs recommended Class B control in May 2025.[9] Most other jurisdictions have not specifically addressed it.
The names parahexyl and synhexyl come from Adams's 1940s laboratory conventions, reflecting the hexyl side chain. The modern abbreviation THCH (or THC-H) follows the pattern of THCP and THCB — appending a letter for the side-chain length. Online, THCH is often bundled into multi-cannabinoid vape blends rather than sold as a standalone product.
Chemistry[edit]
Structural class
THCH belongs to the dibenzopyran family of classical cannabinoids — the same structural family as Δ9-THC. It is a direct homolog of THC, with a six-carbon (hexyl) side chain at C-3 instead of THC's five-carbon (pentyl) chain.[3] In the THC homolog series, each additional carbon increases receptor potency and fat-solubility;[2] a Δ8 isomer also exists and has been found in commercial products.[8]
Molecular identity
| Molecular formula | C₂₂H₃₂O₂ |
| Molecular weight | 328.5 g/mol |
THCH occurs only in trace amounts in cannabis plants — it was first isolated from the FM2 Italian medicinal cannabis variety[3] and is classified as a minor phytocannabinoid.[10] Most commercially available THCH is produced semi-synthetically.
Pharmacology[edit]
Mechanism of action
THCH is a full agonist at the cannabinoid CB1 — unlike Δ9-THC, which is a partial agonist.[11][1] A full agonist can activate CB1 receptors more completely, reaching activation levels that THC cannot achieve.[1] The extra potency comes from its longer side chain, which fits more deeply into a hydrophobic binding groove on the receptor.[2][12]
Pharmacokinetics
No human pharmacokinetic data exist for THCH. Mouse studies identified 16 metabolites, processed primarily through the same liver pathway that handles conventional THC.[13] THCH metabolism shifts toward more hydroxylated breakdown products compared to standard THC.[13]
Neuroscience[edit]
Where it acts
CB1 receptors are the most abundant receptor of their type in the brain, concentrated in regions governing memory (hippocampus), movement (cerebellum), and decision-making (prefrontal cortex). As a full CB1 agonist,[1] THCH suppresses neurotransmitter release throughout these regions. It also triggers dopamine release into the brain's reward circuit, producing the euphoria characteristic of cannabis-type compounds.
Why it matters
The key distinction is full versus partial agonism. THC hits a ceiling at moderate receptor activation; THCH can go further, making effects like anxiety, paranoia, and perceptual disturbance more accessible at lower doses.
Repeated use causes receptors to downregulate — the brain reduces the number of active receptors as compensation, which is the underlying mechanism of tolerance.
No published binding affinity measurements exist for THCH — without those numbers, its exact potency relative to THC and Δ9-THCP is estimated, not measured. The human metabolite profile is also unknown; mouse data identified 16 breakdown products, but whether any are active in ways that shape the experience cannot be predicted from animal studies.
Subjective Effects[edit]
The THCH experience mirrors cannabis in character — sedation, altered time perception, heightened appetite, sensory amplification — but the dose-response curve is steeper. The margin between a comfortable experience and an overwhelming one is narrower than with conventional cannabis, because full receptor activation is pharmacologically accessible where THC's partial agonism cannot reach.
THCH sits between Δ9-THC and Δ9-THCP in the cannabinoid potency series. The qualitative character resembles cannabis, but the risk profile is closer to synthetic cannabinoids — more intensity per dose, less room for error. No controlled human data confirm these characterisations; they rest on pharmacological class inference and adverse event reports.
Effect Grid
At common doses, the full cannabimimetic profile manifests clearly: cognitive euphoria, pronounced sedation, significant thought deceleration, and marked time alteration. Memory suppression is notable — short-term recall becomes unreliable. Humor enhancement and immersion enhancement are prominent. Focus suppression and analysis suppression impair complex cognitive tasks.
Physically, body high intensifies with bodily heaviness and muscle relaxation. Appetite enhancement is strong. Dry mouth is reliable. Motor control impairment becomes apparent in fine movements. Abnormal heartbeat (tachycardia) may be noticed.
Significant functional impairment precludes productive activity. Duration of commitment is unknown — no published data confirm how long the experience lasts at any dose.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Color alteration · Depth perception distortion · Perspective distortion · Proprioceptive distortion · Sound sensitivity · Spatial disorientation · Touch enhancement · Vestibular distortion · Visual haze / noise · Olfactory enhancement · Brightness alteration · Light sensitivity · Visual acuity suppression · Visual processing suppression
Sound sensitivity · Spatial disorientation · Touch enhancement · Vestibular distortion · Visual haze / noise · Olfactory enhancement · Brightness alteration · Light sensitivity · Visual acuity suppression · Visual processing suppression
Sedation · Appetite enhancement · Body scan awareness · Bodily heaviness · Dizziness · Heart rate perception changes · Laughter fits · Pain suppression · Physical fatigue · Temperature dysregulation · Body schema distortion · Nausea suppression · Spontaneous body sensations · Tactile euphoria · Constipation · Nausea · Sexual arousal enhancement · Vomiting · Restlessness · Bodily dissociation
Bodily heaviness · Dizziness · Heart rate perception changes · Laughter fits · Pain suppression · Physical fatigue · Body schema distortion · Nausea suppression · Spontaneous body sensations · Tactile euphoria · Constipation · Nausea · Sexual arousal enhancement · Vomiting · Restlessness · Bodily dissociation
Information processing suppression · Memory fragmentation · Aesthetic enhancement · Analysis suppression · Cognitive euphoria · Immersion enhancement · Humor enhancement · Cognitive fatigue · Conceptual thinking · Confusion · Increased nature relatedness · Introspection enhancement · Language suppression · Motivation suppression · Multiple thought streams · Novelty enhancement · Openness enhancement · Suggestibility enhancement · Thought connectivity · Thought deceleration · Thought disorganization · Thought loops · Creativity enhancement · Memory replays · Cognitive dysphoria · Cognitive flexibility · Compulsive redosing urge · Pattern recognition enhancement · Thought acceleration · Amnesia
Analysis suppression · Cognitive euphoria · Immersion enhancement · Humor enhancement · Cognitive fatigue · Conceptual thinking · Confusion · Increased nature relatedness · Introspection enhancement · Language suppression · Motivation suppression · Multiple thought streams · Novelty enhancement · Openness enhancement · Thought connectivity · Thought deceleration · Thought disorganization · Thought loops · Creativity enhancement · Memory replays · Cognitive dysphoria · Cognitive flexibility · Compulsive redosing urge · Pattern recognition enhancement · Thought acceleration · Amnesia
Emotional enhancement · Simultaneous emotions · Anxiety suppression · Dysphoria · Empathy enhancement · Irritability
Empathy enhancement · Irritability
Emotional susceptibility · Sociability enhancement · Automaticity · Compulsive behavior reduction · Craving · Sociability suppression · Social connection · Social disconnection · Trust enhancement · Flow state · Cognitive disconnection · Boundary dissolution
Craving · Sociability suppression · Social connection · Social disconnection · Trust enhancement · Flow state · Cognitive disconnection · Boundary dissolution
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 21 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- Δ9-THC · Δ8-THC · THCP
Toxicity
No lethal dose, therapeutic index, or controlled toxicity data exist for THCH in any species. safety citation needed
Documented adverse events
Japanese post-market surveillance recorded at least nine safety incidents before THCH was scheduled in August 2023.[5] Reported symptoms included nausea, vomiting, hallucinations, facial and upper-body numbness, uncontrolled eye movements, severe dizziness, and loss of consciousness. One person was unconscious for two days and required ICU admission.
The severity of these events goes well beyond the typical adverse profile of Δ9-THC and is consistent with a more potent CB1 full agonist. No deaths were documented.
Cardiovascular risk
CB1 full agonism raises heart rate through sympathetic nervous system activation, with potential cardiovascular strain in predisposed individuals. THCH's higher potency means these effects may appear at lower doses than with conventional THC. No substance-specific data exist. inferred
Vaping-specific risks
THCH products are frequently sold as vaping liquids.[4][8] THCH acetate (THCH-O), identified in commercial e-cigarette products,[4] shares structural features with acetylated cannabinoids that may produce a highly reactive lung toxicant when heated — a concern paralleling the EVALI crisis. No THCH-O-specific studies have been published. inferred
Detection limitations
Standard drug screening tests show reduced sensitivity for extended-chain THC homologs including THCH.[14] Confirming THCH use requires laboratory mass spectrometry[15][16] — equipment unavailable in most clinical settings. Standard workplace or hospital drug tests may fail to detect THCH use.
Psychological risks
No controlled studies of THCH's psychological effects exist. Risk is inferred from CB1 full agonist pharmacology and Japanese adverse event reports. Full agonists reach higher receptor occupancy than Δ9-THC, making anxiety, paranoia, confusion, and cognitive impairment more accessible at moderate doses.
Hallucinations were documented in Japanese adverse event reports.[5] Psychosis risk is elevated relative to Δ9-THC, particularly in those with a personal or family history of psychotic disorders. inferred Prolonged unconsciousness — documented in at least one Japanese case — is a severe outcome not associated with Δ9-THC at any dose.
Tolerance and dependence
No published tolerance or dependence data specific to THCH exist. Repeated use causes cannabinoid receptors to downregulate,[1] reducing their sensitivity — the same mechanism underlying cannabis tolerance. Cross-tolerance with Δ9-THC and other CB1 agonists is expected.
THCH's full agonist status suggests tolerance may develop faster than with THC, and abuse liability is presumed at least equivalent. Withdrawal is expected to resemble cannabis withdrawal syndrome: irritability, insomnia, appetite disruption, anxiety, and restlessness. inferred
Drug interactions
No published drug interaction studies exist for THCH. All interactions are inferred from Δ9-THC pharmacology. inferred
CNS depressants (alcohol, benzodiazepines, opioids): Combined sedation is additive; with opioids, the risk of dangerously respiratory depression increases. THCH's potency narrows the margin for safe combination use.
CYP2C9 inhibitors (e.g. fluconazole, amiodarone): Slow THCH's liver metabolism, raising plasma levels and prolonging effects.
CYP3A4 inducers (e.g. rifampicin, carbamazepine, St John's Wort): Speed up metabolism, reducing plasma levels and shortening duration.
Stimulants and sympathomimetics: Add to THCH's heart rate elevation.
Product contamination: Documented mislabelling[4] means consumers may unknowingly take additional unlabelled cannabinoids, making individual interaction risk unpredictable.
Contraindications
No substance-specific contraindication studies exist. The following are derived from CB1 full agonist pharmacology. inferred
Absolute:
- Personal or family history of psychotic disorders — CB1 full agonism elevates risk of acute psychosis and may accelerate onset of schizophrenia-spectrum conditions
- Pregnancy and breastfeeding — CB1 receptors are expressed in fetal brain tissue; exogenous agonism disrupts neurodevelopmental signalling
Relative:
- Heart conditions — CB1-mediated heart rate elevation; amplified by full agonist ceiling
- Active or past cannabis use disorder — higher potency and full agonism increase reinforcement and dependence risk
- Concurrent CNS depressant use — additive sedation risk
- Liver impairment — expected reduced clearance
- Adolescence — endocannabinoid system is still developing; exogenous agonism may disrupt brain maturation
Harm Reduction[edit]
Forms & Identification
THCH enters consumer markets primarily as vape cartridges and oil tinctures, often blended with other semi-synthetic cannabinoids. Forensic analyses have consistently found that product labels do not reliably reflect actual contents[4] — a product labelled "THCH" may contain different cannabinoids, different concentrations, or acetylated variants like THCH-O.
Third-party certificates of analysis (COAs) should be verified against the testing laboratory's own records rather than accepted from the vendor at face value. The semi-synthetic cannabinoid market has minimal quality infrastructure; independent testing is the only reliable safeguard.
Guidelines
- Start extremely low. No established human dosing data exist. Begin well below what would be a threshold dose for Δ9-THC and wait for full onset before considering redosing
- Test your product. Given documented mislabelling in the THCH market, test with available reagent kits and verify any COA independently
- Avoid combinations. Do not combine with alcohol, benzodiazepines, opioids, or other CNS depressants — THCH's full agonism narrows the margin for safe combination use
- Do not drive or operate machinery. Cognitive and motor impairment may be more severe and longer-lasting than cannabis experience suggests
- Have a sober companion. Prolonged unconsciousness has been documented — someone should be present who can monitor responsiveness and call for help
- Avoid vaping acetylated products. THCH-O (THCH acetate) may generate toxic byproducts when heated
Set & Setting
THCH's higher potency and full agonist pharmacology make mental state and environment more consequential than with conventional cannabis. A familiar, comfortable setting with a sober companion present is strongly recommended — particularly for first use.
The steeper dose-response curve means a difficult experience can escalate quickly. A trusted person who can offer reassurance or summon help reduces the risk of a manageable situation becoming dangerous.
Aftercare & integration. Post-experience recovery from THCH follows the pattern of other potent cannabinoids. Residual grogginess, mild confusion, or low mood may persist for 12–24 hours. Prioritise hydration, easily digestible food, and sleep. Avoid driving or demanding cognitive tasks until fully baseline.
If the experience was distressing — particularly if it involved prolonged confusion, dissociation, or panic — allow several days before re-evaluating. Persistent anxiety, depersonalisation, or intrusive thoughts beyond 48 hours warrant consultation with a healthcare provider familiar with substance-related concerns.
Recovery & Support
Regular or escalating THCH use may indicate dependence. Full CB1 agonists carry a dependence profile at least equivalent to conventional cannabis, and cannabis use disorder is a recognised clinical condition with effective treatments including cognitive-behavioural therapy and motivational enhancement.
Support resources include SAMHSA's National Helpline (1-800-662-4357), Marijuana Anonymous, and local addiction services. Healthcare providers can assist with managing withdrawal symptoms — irritability, insomnia, and appetite disruption — which may be more pronounced after sustained use of high-potency CB1 agonists.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency: Uncomfortable anxiety and mild confusion during THCH use do not require medical intervention. Seek immediate help if any of the following occur: loss of consciousness or inability to be roused, seizure, chest pain or irregular heartbeat, difficulty breathing, extreme confusion with inability to recognise surroundings or people, or self-harm behaviour.
Immediate steps:
- Call emergency services if the person is unresponsive, seizing, or showing signs of cardiovascular distress
- Place an unconscious but breathing person in the recovery position (on their side, head tilted back)
- Do not leave an unconscious person alone — monitor breathing continuously
- Do not induce vomiting if the product was ingested
- Keep the person warm and in a quiet environment if conscious but distressed
What to tell the dispatcher: State what was taken (THCH or the specific product name), how much, when, the route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Tetrahydrocannabihexol occupies a rapidly evolving regulatory landscape — it has been specifically scheduled in some jurisdictions while remaining unaddressed in most.[17]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| Japan | Designated substance | Both Δ8-THCH and Δ9-THCH designated July 25, 2023; effective August 4, 2023. Manufacturing, import, sale, and non-medical possession prohibited[5][18] |
| United Kingdom | Recommended Class B / Schedule 1 | ACMD recommended control of semi-synthetic THC homologs in May 2025; government accepted recommendation. Consultation on generic cannabinoid text amendment underway as of May 2026.[9] citation needed |
| Czech Republic | Banned | THCH included among 11 additional HHC derivatives banned in July 2024. citation needed |
| France | Banned | THCH banned among cannabinoids structurally related to THC. citation needed |
| European Union | Monitored (EUDA Early Warning System) | Δ8-THCH formally notified to the EU Early Warning System in May 2024.[19] Individual member state scheduling varies |
| United States | Not specifically scheduled; ambiguous | Not scheduled under the Controlled Substances Act. Federal Analogue Act may apply if consumed by humans. Hemp-derived THCH occupies a legal grey zone under the 2018 Farm Bill if total Δ9-THC content remains below 0.3%.[17] citation needed |
| Canada | Not confirmed | Likely captured by generic THC/cannabinoid provisions under the CDSA. citation needed |
| Australia | Not confirmed | Likely captured by generic cannabinoid provisions under the TGA scheduling framework. citation needed |
Analog and prodrug considerations
In the United States, THCH's structural and pharmacological similarity to Δ9-THC may trigger the Federal Analogue Act, which treats substantially similar compounds as controlled substances when intended for human consumption. THCH's demonstrated CB1 full agonism — more potent than Δ9-THC — strengthens that argument. No DEA enforcement action specifically naming THCH has been identified as of May 2026.
THCH acetate (THCH-O), found in commercial vaping products,[4] is a prodrug that converts to THCH in the body. Its regulatory treatment varies by jurisdiction and may require separate scheduling.
Legal status changes frequently and varies by jurisdiction. This information reflects available data as of May 2026 and is not legal advice. Verify current laws in your jurisdiction before taking any action.
references
- [1] ^abcdeJanssens LK, Van Uytfanghe K, Williams JB, Hering KW, Iula DM, Stove CP (2024) Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays - and how this matters for the harm potential of seized drugs — Archives of Toxicology doi:10.1007/s00204-024-03769-4
- [2] ^abcBow EW, Rimoldi JM (2016) The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation — Perspectives in Medicinal Chemistry doi:10.4137/pmc.s32171
- [3] ^abcdLinciano P, Citti C, Russo F, Tolomeo F, Laganà A, Capriotti AL, Luongo L, Iannotta M, Belardo C, Maione S, Forni F, Vandelli MA, Gigli G, Cannazza G (2020) Identification of a new cannabidiol n-hexyl homolog in a medicinal cannabis variety with an antinociceptive activity in mice: cannabidihexol — Scientific Reports doi:10.1038/s41598-020-79042-2
- [4] ^abcdefgWatanabe S, Murakami T, Muratsu S, Fujiwara H, Nakanishi T, Seto Y (2025) Discrepancies between the stated contents and analytical findings for electronic cigarette liquid products: Identification of the new cannabinoid, Δ9-tetrahydrocannabihexol acetate — Drug Testing and Analysis doi:10.1002/dta.3777
- [5]
- [6]